OMNIAB INC (OABI)

US68218J1034 - Common Stock

3.71  +0.03 (+0.82%)

After market: 3.71 0 (0%)

Fundamental Rating

3

OABI gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. OABI has a great financial health rating, but its profitability evaluates not so good. OABI is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OABI has reported negative net income.
In the past year OABI has reported a negative cash flow from operations.
OABI had negative earnings in each of the past 5 years.
In multiple years OABI reported negative operating cash flow during the last 5 years.

1.2 Ratios

OABI has a Return On Assets (-19.01%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -21.60%, OABI is in line with its industry, outperforming 49.12% of the companies in the same industry.
Industry RankSector Rank
ROA -19.01%
ROE -21.6%
ROIC N/A
ROA(3y)-9.22%
ROA(5y)N/A
ROE(3y)-11.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

OABI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

OABI does not have a ROIC to compare to the WACC, probably because it is not profitable.
OABI has more shares outstanding than it did 1 year ago.
There is no outstanding debt for OABI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

OABI has an Altman-Z score of 5.75. This indicates that OABI is financially healthy and has little risk of bankruptcy at the moment.
OABI's Altman-Z score of 5.75 is fine compared to the rest of the industry. OABI outperforms 75.44% of its industry peers.
There is no outstanding debt for OABI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.75
ROIC/WACCN/A
WACC10.88%

2.3 Liquidity

OABI has a Current Ratio of 4.62. This indicates that OABI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.62, OABI is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
A Quick Ratio of 4.62 indicates that OABI has no problem at all paying its short term obligations.
OABI has a Quick ratio of 4.62. This is in the better half of the industry: OABI outperforms 78.95% of its industry peers.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 4.62

More info and screens

4

3. Growth

3.1 Past

The earnings per share for OABI have decreased strongly by -93.75% in the last year.
Looking at the last year, OABI shows a very negative growth in Revenue. The Revenue has decreased by -68.46% in the last year.
OABI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.66% yearly.
EPS 1Y (TTM)-93.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-68.46%
Revenue growth 3Y13.66%
Revenue growth 5YN/A
Sales Q2Q%-23.83%

3.2 Future

OABI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.74% yearly.
Based on estimates for the next years, OABI will show a quite strong growth in Revenue. The Revenue will grow by 17.98% on average per year.
EPS Next Y-14.15%
EPS Next 2Y9.82%
EPS Next 3Y13.67%
EPS Next 5Y15.74%
Revenue Next Year-28.69%
Revenue Next 2Y12.94%
Revenue Next 3Y18.95%
Revenue Next 5Y17.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OABI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OABI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

OABI's earnings are expected to grow with 13.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.82%
EPS Next 3Y13.67%

More info and screens

0

5. Dividend

5.1 Amount

OABI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMNIAB INC

NASDAQ:OABI (1/6/2025, 4:01:20 PM)

After market: 3.71 0 (0%)

3.71

+0.03 (+0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners55.73%
Inst Owner ChangeN/A
Ins Owners5.96%
Ins Owner Change2.37%
Market Cap446.02M
Analysts84.29
Price Target9.82 (164.69%)
Short Float %7.33%
Short Ratio14.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.33%
Min EPS beat(2)-14.18%
Max EPS beat(2)24.84%
EPS beat(4)2
Avg EPS beat(4)1.17%
Min EPS beat(4)-15.52%
Max EPS beat(4)24.84%
EPS beat(8)3
Avg EPS beat(8)8.01%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-10.91%
Min Revenue beat(2)-51.31%
Max Revenue beat(2)29.49%
Revenue beat(4)1
Avg Revenue beat(4)-23.75%
Min Revenue beat(4)-51.31%
Max Revenue beat(4)29.49%
Revenue beat(8)2
Avg Revenue beat(8)-19.52%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.28%
PT rev (3m)-3.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.25%
EPS NY rev (1m)-0.42%
EPS NY rev (3m)-3.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.1%
Revenue NY rev (1m)-0.94%
Revenue NY rev (3m)-15.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.85
P/FCF N/A
P/OCF N/A
P/B 1.53
P/tB 7.01
EV/EBITDA N/A
EPS(TTM)-0.62
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.17
BVpS2.43
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.01%
ROE -21.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.22%
ROA(5y)N/A
ROE(3y)-11.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.24%
Cap/Sales 9.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 4.62
Altman-Z 5.75
F-Score3
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)42.52%
Cap/Depr(5y)28.65%
Cap/Sales(3y)15.2%
Cap/Sales(5y)10.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-14.15%
EPS Next 2Y9.82%
EPS Next 3Y13.67%
EPS Next 5Y15.74%
Revenue 1Y (TTM)-68.46%
Revenue growth 3Y13.66%
Revenue growth 5YN/A
Sales Q2Q%-23.83%
Revenue Next Year-28.69%
Revenue Next 2Y12.94%
Revenue Next 3Y18.95%
Revenue Next 5Y17.98%
EBIT growth 1Y-103.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.62%
EBIT Next 3Y12.42%
EBIT Next 5YN/A
FCF growth 1Y-221.98%
FCF growth 3Y-27.83%
FCF growth 5YN/A
OCF growth 1Y-5003.98%
OCF growth 3Y-13.45%
OCF growth 5YN/A